Literature DB >> 7994325

Willingness to pay for diagnostic services. A new approach to modelling patient benefits in health care.

W Ried1.   

Abstract

The paper investigates the benefit the patient derives from medical diagnosis. By considering explicitly the prospects with respect to both health and monetary consequences resulting from a decision taken by the physician, a fairly general approach to discuss diagnostic services is developed. The willingness to pay of the patient is taken to be measured by his compensating option price, evaluated with respect to the reference state without further diagnostic information. Of particular interest are conditions governing positivity of the patient benefit. Imposing additional restrictions upon individual preferences considerably simplifies the analysis by relying on a loss function. The final section discusses the role of the patient benefit as regards cost-benefit analysis of diagnostic services. If health insurance is available providing at least partial coverage, a positive willingness to pay of the patient net of diagnostic cost can be shown to give no clue as to whether utilization of a diagnostic service is beneficial to society in the sense of cost-benefit analysis.

Entities:  

Mesh:

Year:  1994        PMID: 7994325     DOI: 10.1002/hec.4730030407

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  3 in total

1.  Culture, self-rated health and resource allocation decision-making.

Authors:  V L Wiseman
Journal:  Health Care Anal       Date:  1999

2.  Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).

Authors:  B George; A Harris; A Mitchell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Economic and outcomes assessment of magnetic resonance imaging in the evaluation of headache.

Authors:  J E Jordan; G F Ramirez; W G Bradley; D Y Chen; J B Lightfoote; A Song
Journal:  J Natl Med Assoc       Date:  2000-12       Impact factor: 1.798

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.